GENETHERA, INC. (OTCMKTS:GTHR) Files An 8-K Changes in Registrant’s Certifying AccountantITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
On September 12, 2018, the Chairman of the Board was forced to terminate its engagement relationship with Fruci & Associates II, PLLC CPA Firm, its former independent auditors. There were no disagreements or disputed matters between the Company and Kory Robert Kolterman on any matter of accounting principles or practices, financial statement disclosures, or any matters concerning or related to auditing scope or procedure.
On September 12, 2018 the Board of Directors unanimously voted to formally engage BFBorgers, CPA, PC Certified Public Accountants as the Company’s new independent auditors for the year ended December 31, 2017 and also for the year ended December 31, 2018 including all quarterly reviews and audits thereafter.
ITEM 9.01 EXHIBITS
Exhibit NumberDescription
Exhibit 10.1Dismissal Letter of Fruci & Associates II, PLLC CPA Firm
GENETHERA INC ExhibitEX-10.1 2 exhibit10.1_ex10z1.htm EXHIBIT 10.1 September 12,…To view the full exhibit click here
About GENETHERA, INC. (OTCMKTS:GTHR)
GeneThera, Inc. (GeneThera) is a biotechnology company. The Company focuses on improving food safety by applying the molecular technologies to eradicate cross-over (zoonotic) diseases, such as Johne’s Disease, Mad Cow Disease, Chronic Wasting Disease and E.coli. The Company focuses on developing molecular diagnostic tests, therapeutics and vaccines to help control diseases in animals and humans. GeneThera has developed diagnostic assays for use in the agricultural and veterinary markets. The Company offers specific assays for Chronic Wasting Disease among elk and deer, and Mad Cow Disease among cattle. The Company is engaged in the development of E. coli (predominantly cattle) and Johne’s disease (predominantly dairy cattle and bison) diagnostics. GeneThera’s Integrated Technology Platform (ITP) is the foundation for fast-track ribosomal DNA (rDNA) vaccine development. The Company is working on the development of a recombinant DNA vaccine for Johne’s disease.
